Phase II clinical trial starts evaluating new drug for glioblastoma GDC-0084 (RG7666) which is a novel BBB-penetrating PI3K/mTOR inhibitor displaying a high brain-to-plasma ratio (1.9–3.3). It remarkably impedes the proliferation of five GBM cell lines and suppresses the growth of U-87 MG GBM xenografts through decreasing Akt phosphorylation
